title: Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide.
abstract: In a mouse model of breast carcinoma, the combination of cyclophosphamide and transforming growth factor β1,2,3 (TGFβ1,2,3)-targeting antibody achieved superior antineoplastic effects. This novel paradigm of synergistic chemoimmunotherapy promises to improve the clinical outcome of cancer patients with micrometastases, and thus deserves further investigation.
authors: Basic Science Program; Leidos Biomedical Research, Inc.; Frederick National Laboratory for Cancer Research; Frederick, MD USA ; Laboratory of Molecular Immunoregulation; Cancer Inflammation Program; Center for Cancer Research; National Cancer Institute; Frederick, MD USA.
authors: Xin
authors: X
authors: Chen
authors: Laboratory of Cancer Biology and Genetics; Center for Cancer Research; National Cancer Institute; Frederick, MD USA.
authors: Lalage M
authors: LM
authors: Wakefield
authors: Laboratory of Molecular Immunoregulation; Cancer Inflammation Program; Center for Cancer Research; National Cancer Institute; Frederick, MD USA.
authors: Joost J
authors: JJ
authors: Oppenheim
keywords: anti-TGFβ antibody; chemoimmunotherapy; cyclophosphamide